Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2020 Mar;91(3):330-332.
doi: 10.1136/jnnp-2019-321205. Epub 2019 Dec 24.

Association of subjective cognitive decline with markers of brain pathology in preclinical autosomal dominant Alzheimer's disease

Jennifer R Gatchel  1   2 , Francisco Lopera  3 , Daniel J Norton  1 , Ana Baena  3 , Edmarie Guzman-Velez  1 , Justin S Sanchez  4 , Federico d'Oleire Uquillas  5 , Aaron Schultz  5 , Patrizia Vannini  6 , Arabiye Artola  1 , Rebecca E Amariglio  5   6 , Dorene M Rentz  5   6 , Pierre N Tariot  7   8 , Eric M Reiman  7   8   9   10 , Keith A Johnson  4   5   6 , Reisa A Sperling  5   6 , Gad A Marshall  5   6 , Yakeel T Quiroz  11   5
Affiliations

Association of subjective cognitive decline with markers of brain pathology in preclinical autosomal dominant Alzheimer's disease

Jennifer R Gatchel et al. J Neurol Neurosurg Psychiatry. 2020 Mar.
No abstract available

Keywords: amyloid; autosomal dominant Alzheimer’s Disease; preclinical; presenilin-1; subjective cognitive decline (SCD); tau.

PubMed Disclaimer

Conflict of interest statement

Competing interests: FL is supported by a grant to the Alzheimer’s Prevention Initiative (API) Colombia, funded by Genentech and Banner Alzheimer’s Institute in Arizona. PNT has received consulting fees from Acadia, Abbott Laboratories, AbbVie, AC Immune, Auspex, Boehringer Ingelheim, Chase Pharmaceuticals, Eisai, GliaCure, Insys Therapeutics and Pfizer. He has received consulting fees and research support from AstraZeneca, Avanir, Eli Lilly, Lundbeck, Merck & Co, Roche, and research support only from Amgen, Avid, Biogen, Elan, Functional Neuromodulation (f[nm]), GE Healthcare, Genentech, Novartis and Targacept. PNT has received other research support from the National Institute on Aging and Arizona Department of Health Services and holds stock options in ADAMAS. EMR has received research support from the National Institute on Aging, Novartis/Amgen, Banner Alzheimer's Foundation, Alzheimer's Association, GHR Foundation, F-Prime Biosciences Research Initiative and NOMIS Foundation. He also reports that he is a compensated scientific advisor with Alkahest, Alzheon, Axovant, Denali, Green Valley, United Neuroscience and Zinfandel Pharma. Banner Alzheimer's Institute has contracts with Genentech/Roche, Novartis/Amgen and Avid/Lilly. DMR has served as a consultant for Eli Lilly, Neurotrack and Lundbeck. KAJ has received salary support from Avid Radiopharmaceuticals, and served as a consultant for Eli Lilly, Novartis, Janssen, Roche, Piramal, GE Healthcare, Siemens, ISIS Pharma, AZTherapy and Biogen. RAS has received salary support from Eli Lilly and Janssen Alzheimer Immunotherapy and has served as a consultant for AbbVie, Biogen, Bracket, Genentech, Lundbeck, Merck, Pfizer, Roche and Sanofi. GAM received research salary support from Eisai, Eli Lilly, Janssen Alzheimer Immunotherapy, Novartis and Genentech. He also has served as a consultant for Eisai, Grifols Shared Services North America and Pfizer.

Figures

Figure 1.
Figure 1.
Scatterplots (a-d) showing the unadjusted correlations between SMC (self-report (unfilled circles, dashed-line) and study-partner-report (filled circles, solid line)) as measured by the Memory Complaint Scale (MCS-Spanish version) and age (a); cortical amyloid (PiB retention) (b); entorhinal cortex (EC) tau (FTP retention) (c); and inferior temporal (IT) tau (FTP retention (d); in PSEN1 E280A mutation carriers (n=21). e. Whole-brain unadjusted vertex-wise analyses of tau FTP PET SUVR images in relation to SMC study-partner-report (top panel) and self-report (bottom panel) at the p<0.01 threshold level show regions in the temporal and parietal lobes associated with SMC. Results are displayed as - log(p) at the p<0.01 (unadjusted) threshold level. SMC=Subjective Memory Complaint Scale, Spanish version; PIB=Pittsburgh Compound B; FTP= Flortaucipir; SUVR=standard uptake volume ratio.
See this image and copyright information in PMC

References

    1. Rabin LA, Smart CM, Amariglio RE: Subjective Cognitive Decline in Preclinical Alzheimer’s Disease. Annu Rev Clin Psychol 2017; 13:369–396 - PubMed
    1. Acosta-Baena N, Sepulveda-Falla D, Lopera-Gomez CM, et al.: Pre-dementia clinical stages in presenilin 1 E280A familial early-onset Alzheimer’s disease: a retrospective cohort study. Lancet Neurol 2011; 10:213–220 - PubMed
    1. Buckley RF, Hanseeuw B, Schultz AP, et al.: Region-Specific Association of Subjective Cognitive Decline With Tauopathy Independent of Global beta-Amyloid Burden. JAMA Neurol 2017; 74:1455–1463 - PMC - PubMed
    1. Norton DJ, Amariglio R, Protas H, et al.: Subjective memory complaints in preclinical autosomal dominant Alzheimer disease. Neurology 2017; 89:1464–1470 - PMC - PubMed
    1. Quiroz YT, Sperling RA, Norton DJ, et al.: Association Between Amyloid and Tau Accumulation in Young Adults With Autosomal Dominant Alzheimer Disease. JAMA Neurol 2018; 75:548–556 - PMC - PubMed

Publication types